News & Updates

Show Multimedia Only

$Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement$

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

07 Aug 2025 by

A Chinese man in his late 30s with a history of pulmonary tuberculosis, asthma, and nephritis, all in remission, presented to the clinic in November 2024 with worsening atopic dermatitis (AD). He had previously used oral systemic steroids (up to 30 mg daily) and azathioprine (up to 100 mg daily), with only mild response, leading to the discontinuation of these treatments. Upon examination, the patient exhibited itchy, scaly red patches on his central face, ears, neck, upper trunk, and elbows, with significant erosions. The body surface area involvement was 50 percent. Find out how this patient responded to oral abrocitinib treatment.

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

07 Aug 2025

Hidradenitis suppurativa patients vulnerable to mental disorders

05 Aug 2025 by

Patients with hidradenitis suppurativa (HS) face increased risks of depression and anxiety, as reported in a study.

Hidradenitis suppurativa patients vulnerable to mental disorders

05 Aug 2025

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

31 Jul 2025 by

Higher dietary intake of vitamins E, K1, C, B2, and D appears to mitigate the risk of atopic dermatitis in young Chinese adults from Singapore and Malaysia, as shown in a large study.

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

31 Jul 2025

Is radiologic imaging necessary in cutaneous SCC?

30 Jul 2025 by

Radiologic imaging of high-risk cutaneous squamous cell carcinoma (sSCC) tumours displays unforeseen results such as local invasion and nodal metastasis, which result in changes in management in nearly half of these cases, reveals a study.

Is radiologic imaging necessary in cutaneous SCC?

30 Jul 2025

Abrocitinib, dupilumab restore skin barrier function in AD

30 Jul 2025

Treatment with abrocitinib or dupilumab results in the restoration of skin barrier function in patients with atopic dermatitis (AD), but these therapies show distinct proteomic impacts, according to a study.

Abrocitinib, dupilumab restore skin barrier function in AD

30 Jul 2025

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

30 Jul 2025 by

Secukinumab may facilitate partial erosion repair and prevent enthesiophyte progression in patients with psoriatic arthritis (PsA), according to a phase IV randomized clinical trial (RCT).

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

30 Jul 2025

Daily emollient application in infants a feasible way to reduce AD burden

28 Jul 2025

Daily emollient application in infants helps reduce the cumulative incidence of atopic dermatitis throughout the 2 years of life and may be a feasible way to reduce its burden in communities, according to a study.

Daily emollient application in infants a feasible way to reduce AD burden

28 Jul 2025

Once-daily roflumilast foam may bring relief in psoriasis

26 Jul 2025 by

Treatment with once-daily roflumilast foam appears to improve the signs and symptoms of psoriasis of the scalp and body, with low rates of adverse events, according to the results of the phase III ARRECTOR trial.

Once-daily roflumilast foam may bring relief in psoriasis

26 Jul 2025

BMI, CCI predict biologic response in psoriasis patients

25 Jul 2025

Several factors, including BMI and Charlson Comorbidity Index (CCI), can help predict treatment response among patients with psoriasis, suggests a study.

BMI, CCI predict biologic response in psoriasis patients

25 Jul 2025

Ivarmacitinib shows favourable risk–benefit profile in AD

24 Jul 2025

The selective oral Janus kinase 1 (JAK1) inhibitor ivarmacitinib helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adolescent and adult patients, while having a manageable safety profile, according to a phase III trial.

Ivarmacitinib shows favourable risk–benefit profile in AD

24 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

Hidradenitis suppurativa patients vulnerable to mental disorders

Hidradenitis suppurativa patients vulnerable to mental disorders

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

Is radiologic imaging necessary in cutaneous SCC?

Is radiologic imaging necessary in cutaneous SCC?

Abrocitinib, dupilumab restore skin barrier function in AD

Abrocitinib, dupilumab restore skin barrier function in AD

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

Daily emollient application in infants a feasible way to reduce AD burden

Daily emollient application in infants a feasible way to reduce AD burden

Once-daily roflumilast foam may bring relief in psoriasis

Once-daily roflumilast foam may bring relief in psoriasis

BMI, CCI predict biologic response in psoriasis patients

BMI, CCI predict biologic response in psoriasis patients

Ivarmacitinib shows favourable risk–benefit profile in AD

Ivarmacitinib shows favourable risk–benefit profile in AD